Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetic Nephropathy AND Diabetes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    98 result(s) found for: Diabetic Nephropathy AND Diabetes. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-004467-65 Sponsor Protocol Number: DNTx Start Date*: 2007-04-24
    Sponsor Name:Technical University Dresden
    Full Title: Influence of pioglitazone for renal transplant function in diabetics
    Medical condition: nephropathy after renal transplantation in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002491-40 Sponsor Protocol Number: CLMB763X2202 Start Date*: 2019-04-03
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized patient-and-physician blinded, placebo-controlled, 24-week study to assess the safety, tolerability and efficacy of LMB763 in patients with diabetic nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002480-98 Sponsor Protocol Number: MT-3995-E06 Start Date*: 2012-10-26
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral...
    Medical condition: Type II Diabetes Mellitus with Nephropathy and Albuminuria
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-002095-15 Sponsor Protocol Number: KRX-101-401 Start Date*: 2005-10-12
    Sponsor Name:Keryx Biopharmaceuticals, Inc.
    Full Title: The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy
    Medical condition: Overt Type 2 Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061835 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000722-19 Sponsor Protocol Number: M12-919 Start Date*: 2016-10-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003332-23 Sponsor Protocol Number: B1261007 Start Date*: 2013-03-21
    Sponsor Name:Pfizer Inc., 235 42nd Street, New York, NY 10017, USA
    Full Title: A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonis...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-011255-44 Sponsor Protocol Number: 2009-278 Start Date*: 2009-08-19
    Sponsor Name:Steno Diabetes Center
    Full Title: The effect of paricalcitol versus placebo on plasma NT-proBNP in patients with type 1 diabetes mellitus and diabetic nephropathy
    Medical condition: Diabetes mellitus type 1 and diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10012638 Diabetes with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002262-31 Sponsor Protocol Number: MS700461-0035 Start Date*: 2017-03-17
    Sponsor Name:Merck KGaA
    Full Title: A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000786-32 Sponsor Protocol Number: SPP301CRD21 Start Date*: 2008-06-17
    Sponsor Name:Speedel Pharma Ltd
    Full Title: A Randomised, Double-blind, Placebo-Controlled, Dose-ranging, Parallel Design Study to Evaluate the Efficacy and Safety of the Endothelin Antagonist Avosentan in Patients With Diabetic Kidney Disease
    Medical condition: Diabetic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012687 Diabetic renal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) LV (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003049-16 Sponsor Protocol Number: CL007_140 Start Date*: 2011-08-29
    Sponsor Name:ChemoCentryx, Inc
    Full Title: A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus, nephropathy, albuminuria
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    14.0 10038359 - Renal and urinary disorders 10027525 Microalbuminuria PT
    14.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    14.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003053-37 Sponsor Protocol Number: 21952 Start Date*: 2021-11-05
    Sponsor Name:Bayer AG
    Full Title: A non-blinded retrospective biomarker add-on study to FIGARO-DKD for Bioprofiling the pharMacodynamic response to finerenone in FIGARO-DKD subjects (FIGARO-BM)
    Medical condition: Type II Diabetes Mellitus and Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003618-17 Sponsor Protocol Number: ALT-711-0424 Start Date*: 2008-05-07
    Sponsor Name:JDRF Danielle Alberti Memorial Centre For Diabetes Complications Baker Heart Research Institute
    Full Title: A Randomozed, Placebo-Controlled Trial of Alagebrium in Patients with Insulin-Dependent Type 1 Diabetes and Microalbuminuria
    Medical condition: This is a double-blind phase 2 clinical study to evaluate the effects of alagebrium chloride (ALT-711) versus placebo on albumin excretion rate (as an early marker of diabetic nephropathy) in subje...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002349-23 Sponsor Protocol Number: 8232-CL-0004 Start Date*: 2015-01-26
    Sponsor Name:Astellas Pharma Europe BV (APEB)
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Recep...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) HU (Completed) CZ (Completed) DE (Completed) BE (Completed) IT (Completed) NL (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021922-36 Sponsor Protocol Number: 2010-352-UREMINC Start Date*: 2011-05-23
    Sponsor Name:Department of Nephrology, Rigshospitalet, University of Copenhagen
    Full Title: Safety and effect of liraglutide in patients with type 2 diabetes and severe renal insufficiency.
    Medical condition: 1) Patients with type 2 diabetes (T2D) and no or severely reduced kidney function, depending on chronic dialysis treatment. 2) Patients with T2D and normal kidney function.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10041244 - Social circumstances 10012347 Dependence on renal dialysis LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005954-62 Sponsor Protocol Number: AIFA MICRO Start Date*: 2007-01-25
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A prospective, randomized, open label blinded end point probe trial to evaluate whether, at comparable blood pressure control, combined therapy with the ACE inhibitor Benazepril and the angiotens...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061835 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005482-12 Sponsor Protocol Number: GLP-1-2012-01 Start Date*: 2013-04-15
    Sponsor Name:University College Dublin
    Full Title: The effect of glucagon-like-peptide 1 (GLP-1) analogues on inflammation in humans with diabetic kidney disease.
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10012687 Diabetic renal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002929-28 Sponsor Protocol Number: 1366-0005 Start Date*: 2021-09-10
    Sponsor Name:Boehringer Ingelheim B. V.
    Full Title: Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in p...
    Medical condition: diabetic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) PT (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005985-10 Sponsor Protocol Number: PTF-REN-001 Start Date*: 2008-03-03
    Sponsor Name:Juan Francisco Navarro González
    Full Title: Análisis del Efecto Renoprotector de la Pentoxifilina en Pacientes con Enfermedad Renal Crónica Secundaria a Nefropatía Diabética
    Medical condition: Enfermedad renal crónica secundaria a nefropatía diabética.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002328-40 Sponsor Protocol Number: HHSC/005 Start Date*: 2007-05-18
    Sponsor Name:Imperial College London
    Full Title: A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant.
    Medical condition: Diabetes mellitus type 1 and succesful renal transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012638 Diabetes with renal manifestations LLT
    9.1 10038533 Renal transplant LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004523-19 Sponsor Protocol Number: TIP0305 Start Date*: 2008-02-08
    Sponsor Name:Área de Trasplante y Terapia Celular - Hospital Central de Asturias
    Full Title: Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant patients.
    Medical condition: Type-I Diabetes Mellitus in renal trasplant patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061835 pt
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 08:24:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA